VRTX:NGS-Vertex Pharmaceuticals Incorporated (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 417.32

Change

-1.14 (-0.27)%

Market Cap

USD 21.38B

Volume

0.91M

Analyst Target

USD 306.43
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

N/A

USD 96.94B
MRNA Moderna Inc

N/A

USD 38.83B
ARGX argenx NV ADR

N/A

USD 22.16B
BNTX BioNTech SE

N/A

USD 21.93B
GMAB Genmab AS

N/A

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 18.12B
RPRX Royalty Pharma Plc

N/A

USD 16.73B
BGNE BeiGene Ltd

N/A

USD 16.68B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.35B
SRPT Sarepta Therapeutics Inc

N/A

USD 12.17B

ETFs Containing VRTX

DCCHAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

USD 0.07B
DCUSAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

USD 0.06B
DCEUAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

USD 0.02B
DCGBAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

USD 2.00M
BBH VanEck Biotech ETF 9.64 % 0.35 %

N/A

USD 0.41B
CURE:XETRA VanEck Genomics and Healt.. 8.72 % 0.00 %

N/A

USD 6.89M
IBB iShares Biotechnology ETF 8.34 % 0.47 %

N/A

USD 6.95B
MSGR 8.22 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 8.19 % 0.00 %

N/A

USD 0.03B
BTEC:SW iShares Nasdaq US Biotech.. 8.09 % 0.00 %

N/A

USD 0.46B
BIS ProShares UltraShort Nasd.. 7.21 % 0.95 %

N/A

USD 3.52M
UBIO 6.52 % 0.95 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 6.01 % 0.95 %

N/A

USD 0.08B
LIFE-U:CA Evolve Global Healthcare .. 5.00 % 0.00 %

N/A

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.92 % 0.00 %

N/A

USD 3.51M
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.80 % 0.00 %

N/A

USD 0.15B
XNNV:XETRA Xtrackers MSCI Innovation.. 4.76 % 0.00 %

N/A

USD 7.55M
XGES:LSE Xtrackers MSCI Genomic He.. 4.30 % 0.00 %

N/A

USD 3.51M
XNNS:LSE Xtrackers MSCI Innovation.. 4.22 % 0.00 %

N/A

USD 7.55M
XNNV:LSE Xtrackers MSCI Innovation.. 4.22 % 0.00 %

N/A

USD 7.55M
BIOT:SW L&G Pharma Breakthrough U.. 4.14 % 0.00 %

N/A

N/A
XDGI:XETRA Xtrackers MSCI Global SDG.. 3.76 % 0.00 %

N/A

USD 0.01B
HEAL:CA 3.39 % 0.00 %

N/A

N/A
CACG ClearBridge All Cap Growt.. 3.07 % 0.53 %

N/A

USD 0.13B
CDNA:CA CI Bio-Revolution ETF 2.92 % 0.00 %

N/A

CAD 4.55M
UPWD 2.43 % 0.00 %

N/A

N/A
SPME:SW iShares Edge S&P 500 Mini.. 2.41 % 0.00 %

N/A

USD 0.09B
SPLV:SW iShares Edge S&P 500 Mini.. 2.41 % 0.00 %

N/A

USD 1.93B
TGGR:CA TD Active Global Equity G.. 2.24 % 0.00 %

N/A

CAD 0.03B
XLVE:CA Mulvihill U.S. Health Car.. 1.69 % 0.00 %

N/A

CAD 6.58M
MVEA:SW iShares Edge MSCI USA Min.. 1.65 % 0.00 %

N/A

USD 0.32B
ESMV iShares ESG MSCI USA Min .. 1.60 % 0.00 %

N/A

USD 0.01B
XWEB:XETRA Xtrackers MSCI World Mini.. 1.43 % 0.00 %

N/A

USD 0.01B
MVEC:SW iShares Edge MSCI World M.. 1.40 % 0.00 %

N/A

USD 0.15B
MVEW:SW iShares Edge MSCI World M.. 1.40 % 0.00 %

N/A

USD 0.61B
MVWE:SW iShares Edge MSCI World M.. 1.40 % 0.00 %

N/A

USD 0.07B
MVEW:LSE iShares Edge MSCI World M.. 1.35 % 0.00 %

N/A

USD 0.61B
FLXU:SW Franklin U.S. Equity UCIT.. 1.11 % 0.00 %

N/A

USD 0.17B
THNZ:XETRA L&G Global Thematic ESG E.. 0.81 % 0.00 %

N/A

USD 4.28M
DEF 0.00 % 0.59 %

N/A

N/A
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

N/A

USD 0.11B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

USD 0.23B
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

N/A

USD 0.02B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.49B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.49B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.49B
VLQ:CA 0.00 % 0.40 %

N/A

N/A
ZBIO 0.00 % 0.95 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

N/A

CAD 0.30B
MVUS:LSE iShares VI Public Limited.. 0.00 % 0.00 %

N/A

USD 1.98B
SMRG:LSE 0.00 % 0.00 %

N/A

N/A
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 0.40M
VMOM:LSE 0.00 % 0.00 %

N/A

N/A
SMRT:PA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 0.03B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
SM8T:F Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
SM8T:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 0.04B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
ZINN:CA 0.00 % 0.00 %

N/A

N/A
MVEA:XETRA iShares Edge MSCI USA Min.. 0.00 % 0.00 %

N/A

USD 0.32B
MVEW:XETRA iShares Edge MSCI World M.. 0.00 % 0.00 %

N/A

USD 0.78B
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

N/A

USD 0.07B
NVQ 0.00 % 0.00 %

N/A

N/A
SMRU:PA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 3.29M
XMLH:F Legal & General Ucits Etf.. 0.00 % 0.00 %

N/A

USD 0.08B
DOCT:SW L&G Healthcare Breakthrou.. 0.00 % 0.00 %

N/A

USD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.56% 50% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.56% 50% F 57% F
Trailing 12 Months  
Capital Gain 32.80% 72% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.80% 72% C 80% B-
Trailing 5 Years  
Capital Gain 126.87% 86% B+ 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 126.87% 86% B+ 85% B
Average Annual (5 Year Horizon)  
Capital Gain 20.55% 73% C 80% B-
Dividend Return 20.55% 73% C 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.46% 88% B+ 64% D
Risk Adjusted Return 72.22% 98% N/A 92% A
Market Capitalization 21.38B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.93 19% 32%
Price/Book Ratio 6.11 24% 19%
Price / Cash Flow Ratio 30.36 3% 10%
Price/Free Cash Flow Ratio 21.06 2% 11%
Management Effectiveness  
Return on Equity 22.99% 98% 91%
Return on Invested Capital 18.99% 88% 88%
Return on Assets 13.17% 100% 97%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.